| 000 | 01705 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513214137.0 | ||
| 264 | 0 | _c20001031 | |
| 008 | 200010s 0 0 eng d | ||
| 022 | _a0959-4973 | ||
| 024 | 7 |
_a10.1097/00001813-200004000-00005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKnuuttila, A | |
| 245 | 0 | 0 |
_aDocetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study. _h[electronic resource] |
| 260 |
_bAnti-cancer drugs _cApr 2000 |
||
| 300 |
_a257-61 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCamptothecin _xadministration & dosage |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMesothelioma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 |
_aPleural Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTaxoids |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aOllikainen, T | |
| 700 | 1 | _aHalme, M | |
| 700 | 1 | _aMali, P | |
| 700 | 1 | _aKivisaari, L | |
| 700 | 1 | _aLinnainmaa, K | |
| 700 | 1 | _aJekunen, A | |
| 700 | 1 | _aMattson, K | |
| 773 | 0 |
_tAnti-cancer drugs _gvol. 11 _gno. 4 _gp. 257-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00001813-200004000-00005 _zAvailable from publisher's website |
| 999 |
_c10848911 _d10848911 |
||